A gain of function ryanodine receptor 2 mutation (R1760W-RyR2) in catecholaminergic polymorphic ventricular tachycardia.
calcium leak
catecholaminergic polymorphic ventricular tachycardia
ryanodine receptor
sudden cardiac death
Journal
Clinical and experimental pharmacology & physiology
ISSN: 1440-1681
Titre abrégé: Clin Exp Pharmacol Physiol
Pays: Australia
ID NLM: 0425076
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
28
08
2022
received:
14
04
2022
accepted:
07
09
2022
pubmed:
10
9
2022
medline:
15
12
2022
entrez:
9
9
2022
Statut:
ppublish
Résumé
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia syndrome associated with Ca
Identifiants
pubmed: 36082968
doi: 10.1111/1440-1681.13722
doi:
Substances chimiques
Ryanodine Receptor Calcium Release Channel
0
RyR2 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
39-49Informations de copyright
© 2022 John Wiley & Sons Australia, Ltd.
Références
Connell P, Word TA, Wehrens XHT. Targeting pathological leak of ryanodine receptors: preclinical progress and the potential impact on treatments for cardiac arrhythmias and heart failure. Expert Opin Ther Targets. 2020;24(1):25-36.
Wleklinski MJ, Kannankeril PJ, Knollmann BC. Molecular and tissue mechanisms of catecholaminergic polymorphic ventricular tachycardia. J Physiol. 2020;598:2817-2834.
Offerhaus JA, Bezzina CR, Wilde AAM. Epidemiology of inherited arrhythmias. Nat Rev Cardiol. 2020;17(4):205-215.
Antoine Leenhardt VL, Denjoy I, Grau F, do Ngoc D, Coumel P. Catecholaminergic polymorphic ventricular tachycardia in children a 7-year follow-up of 21 patients. Circulation. 1995;91:1512-1519.
van der Werf C, Zwinderman AH, Wilde AA. Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments. Europace. 2012;14(2):175-183.
Priori S, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002;106(1):69-74.
Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Heart Rhythm. 2018;15(10):e73-e189.
Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation. 2009;119(18):2426-2434.
Hayashi M, Denjoy I, Hayashi M, et al. The role of stress test for predicting genetic mutations and future cardiac events in asymptomatic relatives of catecholaminergic polymorphic ventricular tachycardia probands. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European society of. Cardiology. 2012;14(9):1344-1351.
Xiao Z, Guo W, Sun B, et al. Enhanced cytosolic Ca2+ activation underlies a common defect of central domain cardiac ryanodine receptor mutations linked to arrhythmias. J Biol Chem. 2016;291(47):24528-24537.
Pan X, Philippen L, Lahiri S, et al. In vivo Ryr2 editing corrects Catecholaminergic polymorphic ventricular tachycardia. Circ Res. 2018;123(8):953-963.
Bers DM. Cardiac excitation-contraction coupling. Nature. 2002;415(6868):198-205.
Naja Dam Mygind, Marie Mide Michelsen, Adam Pena, Abbas Ali Qayyum, Daria Frestad4, Thomas Emil Christensen, et al. Coronary microvascular function and myocardial fibrosis in women with angina pectoris and no obstructive coronary artery disease: the iPOWER study J Cardiovasc Magn Reson. 2016;18.76.
Pérez-Riera AR, Barbosa-Barros R, de Rezende Barbosa MPC, Daminello-Raimundo R, de Lucca AA Jr, de Abreu LC. Catecholaminergic polymorphic ventricular tachycardia, an update. Ann Noninvasive Electrocardiol. 2018;23(4):e12512.
Hirose S, Murayama T, Tetsuo N, et al. Loss-of-function mutations in cardiac ryanodine receptor channel cause various types of arrhythmias including long QT syndrome. Europace. 2022;24(3):497-510.
Jiang D, Wang R, Xiao B, et al. Enhanced store overload-induced Ca2+ release and channel sensitivity to luminal Ca2+ activation are common defects of RyR2 mutations linked to ventricular tachycardia and sudden death. Circ Res. 2005;97(11):1173-1181.
Jiang D, Xiao B, Yang D, et al. RyR2 mutations linked to ventricular tachycardia and sudden death reduce the threshold for store-overload-induced Ca2+ release (SOICR). Proc Natl Acad Sci. 2004;101(35):13062-13067.
Meli AC, Refaat MM, Dura M, et al. A novel ryanodine receptor mutation linked to sudden death increases sensitivity to cytosolic calcium. Circ Res. 2011;109(3):281-290.
Kryshtal DO, Blackwell DJ, Egly CL, et al. RYR2 channel inhibition is the principal mechanism of Flecainide action in CPVT. Circ Res. 2021;128(3):321-331.
Hwang HS, Hasdemir C, Laver D, et al. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol. 2011;4(2):128-135.
Smith CD, Wang A, Vembaiyan K, et al. Novel carvedilol analogues that suppress store-overload-induced Ca2+ release. J Med Chem. 2013;56(21):8626-8655.
Zhong X, Sun B, Vallmitjana A, et al. Suppression of ryanodine receptor function prolongs Ca2+ release refractoriness and promotes cardiac alternans in intact hearts. Biochem J. 2016;473(21):3951-3964.
Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the Management of Patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793-2867.
Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in may 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013;10(12):1932-1963.
Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene. 1989;77(1):51-59.
Meng X, Xiao B, Cai S, et al. Three-dimensional localization of serine 2808, a phosphorylation site in cardiac ryanodine receptor. J Biol Chem. 2007;282(35):25929-25939.
Kumar P, Nagarajan A, Uchil PD. Calcium phosphate-mediated transfection of cells with high-molecular-weight genomic DNA. Cold Spring Harb Protoc. 2019;2019(10):pdb.prot095448.
Chen W, Koop A, Liu Y, et al. Reduced threshold for store overload-induced ca(2+) release is a common defect of RyR1 mutations associated with malignant hyperthermia and central core disease. Biochem J. 2017;474(16):2749-2761.
Palmer AE, Jin C, Reed JC, Tsien RY. Bcl-2-mediated alterations in endoplasmic reticulum Ca2+ analyzed with an improved genetically encoded fluorescent sensor. Proc Natl Acad Sci U S A. 2004;101(50):17404-17409.
Yuchi Z, Van Petegem F. Ryanodine receptors under the magnifying lens: insights and limitations of cryo-electron microscopy and X-ray crystallography studies. Cell Calcium. 2016;59(5):209-227.
Meissner G. Ryanodine receptor:Ca2+ release channels and their regulation by endogenous effectors. Annu Rev Physiol. 1994;56:485-508.
Priori SG, Chen SR. Inherited dysfunction of sarcoplasmic reticulum Ca2+ handling and arrhythmogenesis. Circ Res. 2011;108(7):871-883.
Medeiros-Domingo A, Bhuiyan ZA, Tester DJ, et al. The RYR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: a comprehensive open reading frame mutational analysis. J Am Coll Cardiol. 2009;54(22):2065-2074.
Shigemizu D, Aiba T, Nakagawa H, et al. Exome analyses of long QT syndrome reveal candidate pathogenic mutations in Calmodulin-interacting genes. PLoS One. 2015;10(7):e0130329.
Flucher SBA BE, Fleischer S, Marks AR, Caswell A, Powell JA. Triad formation-organization and function of the sarcoplasmic reticulum calcium release channel and triadin in normal and dysgenic muscle in vitro. J Cell Biol. 1993;1993(123):1161-1174.
Franzini-Armstrong C, Protasi F, Tijskens P. The assembly of calcium release units in cardiac muscle. Ann N Y Acad Sci. 2005;1047:76-85.
Jones PP, Jiang D, Bolstad J, et al. Endoplasmic reticulum Ca2+ measurements reveal that the cardiac ryanodine receptor mutations linked to cardiac arrhythmia and sudden death alter the threshold for store-overload-induced Ca2+ release. Biochem J. 2008;412(1):171-178.
MacLennan DH, Chen SR. Store overload-induced Ca2+ release as a triggering mechanism for CPVT and MH episodes caused by mutations in RYR and CASQ genes. J Physiol. 2009;587(Pt 13):3113-3115.
Kanaporis G, Blatter LA. The mechanisms of calcium cycling and action potential dynamics in cardiac alternans. Circ Res. 2015;116(5):846-856.
Jiang D, Chen W, Wang R, Zhang L, Chen SRW. Loss of luminal Ca2+ activation in the cardiac ryanodine receptor is associated with ventricular fibrillation and sudden death. Proc Natl Acad Sci. 2007;104(46):18309-18314.
Fabiato A. Time and calcium dependence of activation and inactivation of calcium-induced release of calcium from the sarcoplasmic reticulum of a skinned canine cardiac Purkinje cell. J Gen Physiol. 1985;85:247-289.
Fabiato A. Two kinds of calcium-induced release of calcium from the sarcoplasmic reticulum of skinned cardiac cells. Adv Exp Med Biol. 1992;311:245-262.
Zhou Q, Xiao J, Jiang D, et al. Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release. Nat Med. 2011;17(8):1003-1009.
Martinez-Hernandez E, Blatter LA. Effect of carvedilol on atrial excitation-contraction coupling, ca release and arrhythmogenicity. Am J Physiol Heart Circ Physiol. 2020;318:1245-1255.